Ian D. Pavord
University of Oxford
667 Papers
5.3K Citations
Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Medicine. The author has an hindex of 108, co-authored 575 publications. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.
Chat about Author
Papers
Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma.
Richard Beasley,Richard Beasley,James Harper,Grace Bird,Harriette Dunphy,Alex Semprini,Ian D. Pavord,Alberto Papi,Mark Weatherall,Mark Weatherall +9 more
TL;DR: The limited available evidence suggests that budesonid/formoterol reliever therapy has greater potency and efficacy than budesonide/ formoterol fixed dose maintenance plus SABA reliever therapy in reducing the risk of a severe exacerbation.
Fevipiprant (qaw039) Reduces Airway Smooth Muscle Mass In Asthma Via Antagonism Of The Prostaglandin D2 Receptor 2 (dp2)
Ruth Saunders,Himanshu Kaul,Rachid Berair,Amisha Singapuri,I Chernyaysky,Latifa Chachi,Michael Biddle,Amanda Sutcliffe,M Laurencin,Gerald Bacher,Michelle Bourne,Ian D. Pavord,Andrew J. Wardlaw,Salman Siddiqui,Richard Kay,Bindi S. Brook,Rod Smallwood,C E Brightling +17 more
- 01 Jan 2017
9
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups
Jaclyn A. Smith,Surinder S. Birring,Peter V. Dicpinigaitis,Lorcan McGarvey,Alyn H. Morice,Ian D. Pavord,Imran Satia,Stuart A. Green,Beata Iskold,Carmen La Rosa,Qing Li,Allison Martin Nguyen,J. Schelfhout,David Muccino +13 more
TL;DR: In this article , the efficacy of gefapixant 45 mg vs placebo was evaluated across COUGH-1/COUGH-2 in predefined subgroups based on sex, region, age, cough duration, cough severity, cough frequency, and diagnosis (RCC, UCC).
Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study
Emma Wilson,Tricia M. McKeever,Beverley Hargadon,Glenn Hearson,John Anderson,David Hodgson,Helen Bailey,Garry Meakin,Mike Thomas,Ian D. Pavord,Tim Harrison,Dominick E. Shaw +11 more
TL;DR: Whether exhaled nitric oxide fraction measurements could predict a loss of symptom control or exacerbation following a reduction in ICS dose in a cohort study of people with well-controlled asthma recruited from primary care is assessed.
9